Supplementary Table 3 from Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer
journal contribution
posted on 2023-03-31, 18:08 authored by Leanne Stevenson, Wendy L. Allen, Richard Turkington, Puthen V. Jithesh, Irina Proutski, Gail Stewart, Heinz-Josef Lenz, Sandra Van Schaeybroeck, Daniel B. Longley, Patrick G. JohnstonPDF file - 183K, Gene set enrichment analysis
History
ARTICLE ABSTRACT
Purpose: A major factor limiting the effective clinical management of colorectal cancer (CRC) is resistance to chemotherapy. Therefore, the identification of novel, therapeutically targetable mediators of resistance is vital.Experimental design: We used a CRC disease-focused microarray platform to transcriptionally profile chemotherapy-responsive and nonresponsive pretreatment metastatic CRC liver biopsies and in vitro samples, both sensitive and resistant to clinically relevant chemotherapeutic drugs (5-FU and oxaliplatin). Pathway and gene set enrichment analyses identified candidate genes within key pathways mediating drug resistance. Functional RNAi screening identified regulators of drug resistance.Results: Mitogen-activated protein kinase signaling, focal adhesion, cell cycle, insulin signaling, and apoptosis were identified as key pathways involved in mediating drug resistance. The G-protein–coupled receptor galanin receptor 1 (GalR1) was identified as a novel regulator of drug resistance. Notably, silencing either GalR1 or its ligand galanin induced apoptosis in drug-sensitive and resistant cell lines and synergistically enhanced the effects of chemotherapy. Mechanistically, GalR1/galanin silencing resulted in downregulation of the endogenous caspase-8 inhibitor FLIPL, resulting in induction of caspase-8–dependent apoptosis. Galanin mRNA was found to be overexpressed in colorectal tumors, and importantly, high galanin expression correlated with poor disease-free survival of patients with early-stage CRC.Conclusion: This study shows the power of systems biology approaches to identify key pathways and genes that are functionally involved in mediating chemotherapy resistance. Moreover, we have identified a novel role for the GalR1/galanin receptor–ligand axis in chemoresistance, providing evidence to support its further evaluation as a potential therapeutic target and biomarker in CRC. Clin Cancer Res; 18(19); 5412–26. ©2012 AACR.Usage metrics
Categories
Keywords
Cell Death And SenescenceCaspasesSurvival factorsChemotherapyCombination chemotherapyComputational MethodsGene expression profilingDrug Discovery TechnologiesScreening strategies (assays and chemical libraries)Drug ResistanceReversal of drug resistanceDrug TargetsCell surface receptor drug targetsGastrointestinal CancersColorectal cancerTumor Staging
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC